Coronavirus and Multiple Sclerosis, Autopsy and Biopsy and Choice of Therapy

Le résumé fourni par la source

Background: Coronavirus in trigeminal nerve (TGN) has for decades been studied as a candidate neurotropic virus associated with multiple sclerosis (MS).The novel coronavirus 2019 (COVID-19) outbreak in infected cases is challenging the whole immune system.The lesson from MS treatment and a new era of COVID-19 therapies are of value to review.Method: Searched databases to identify the strongest evidence of biopsy, autopsy, and cerebrospinal fluid (CSF), when using keywords MS and coronavirus, from January 1940 to April 2020.The result presents a solid knowledge of biopsy and autopsy for the association of COVID-19 and MS, then COVID-19 single and combination therapies being evaluated as presented in clinical use or clinical trials and compare common sites with MS.Results: All therapies with proven clinical efficacy against COVID-19 and its current deployment in COVID-19 and their common aspect with MS therapies (MSTR) and immunology are screened.Some MSTR despite some different side-effect e.g.risk for infection or cardiac arrest are candidates of being used as COVID-19 life-saving therapy.Conclusion: This global health disaster caused by airborne virus COVID-19, has created a new break to learn more about MS etiology and this airborne agent and future drug choices when reviewing the five months COVID-19 data through significant medical reports on World Wide Web.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.